|
| | 
|
 | |
        
|  |
 
|
| PS: The quotes after 2010-12-09 are still temporary and may have for that reason the Open values wrong until furter updates...
Change to ADC Telecommunica Static Chart |
 ADC Telecommunica - [Ticker: ADCT] |     | | Last Trade | 0.00 | Last Trade Time | - 00:00:00 | | Variation | N/A (N/A) | Open | 0.00 | | High | 0.00 | Low | 0.00 | | Volume | 0 | Average Volume (3m) | 0 | | Yield | | Bid / Ask | N/A | | Former Close | 0.00 | 52 Week Range | [0.00 - 0.00] | | PER | 0.00% | EPS | 0.00 | | Ex-Dividend Date | | Dividend Payment | | | Market Capitalization | 0 | 1 Year Price-Target | 0.00 | | Note: The data may have some minutes of delay. |
|
News about ADC Telecommunica [ADCT]: (ordered by relevance)
| | ADC Therapeutics SA (NYSE:ADCT) to Post FY2022 Earnings of ($3.06) Per Share, Cantor Fitzgerald Forecasts MarketBeat
30 Stocks Moving In Friday's Mid-Day Session Markets Insider
Application Delivery Controller (ADC) Market to Witness Huge Growth by 2028 | A10 Networks Inc., Citrix Systems Inc., F5 Networks Inc. Digital Journal
ADC Therapeutics SA (ADCT) Q3 2021 Earnings Call Transcript Motley Fool
ADC Therapeutics Doses First Patient in Phase 1 Clinical Trial of ADCT-901 in Advanced Solid Tumors Business Wire
ADC Therapeutics Enters Into a Financing Agreement with HealthCare Royalty for Up to $325 Million Business Wire
Latest business liquidations in Unincorporated ACT Daily Telegraph
ADC Therapeutics Announces Validation of its Marketing Authorization Application by the European Medicines Agency for ZYNLONTAŽ Business Wire
ADC Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Updates Business Wire
Overland ADCT BioPharma Announces First Patient Dosed in China with ZYNLONTAŽ in Pivotal Phase 2 Clinical Trial for Diffuse Large B-cell Lymphoma Business Wire
ADC Therapeutics Receives Orphan Drug Designation in Europe for ZYNLONTAŽ Business Wire
ADC Therapeutics and Overland Pharmaceuticals Announce Formation of Overland ADCT BioPharma to Develop and Commercialize Lonca and other ADCs for Hematologic and Solid Tumor Indications in Greater China and Singapore Business Wire
ADC Therapeutics Announces Encouraging Interim Results from Pivotal Phase 2 Clinical Trial of Camidanlumab Tesirine (Cami) Presented at the 16th Annual International Conference on Malignant Lymphoma Business Wire
ADC Therapeutics Reports Fourth Quarter and Year-End 2020 Financial Results and Provides Business Updates Business Wire
ADC Therapeutics Announces FDA Approval of ZYNLONTA? (loncastuximab tesirine-lpyl) in Relapsed or Refractory Diffuse Large B-Cell Lymphoma BioSpace
ADC Therapeutics Announces Presentations at the 16th Annual International Conference on Malignant Lymphoma Business Wire
Overland ADCT BioPharma Appoints Eric Koo as Chief Executive Officer Business Wire
ADC Therapeutics Announces Receipt of $50 Million Second Tranche of Convertible Credit Facility with Deerfield Business Wire
Coming together for Zynlonta Cancer Research UK
Jennifer Herron, of ADC Therapeutics, Joins Genocea Biosciences' Board of Directors Yahoo Finance
ADC Therapeutics to develop anti-cancer drugs in new White City Campus centre Imperial College London
2022: Stakeholders call on Nigerians to participate in ICT/telecoms sector Daily Sun
ADC Therapeutics Receives FDA Approval For Zynlonta Contract Pharma
The Internet Heist (Part II). From broadcast flags to the analog hole | by Cory Doctorow | Jan, 2022 | OneZero OneZero
ADC Therapeutics Announces the Termination of its ADCT-502 Program Targeting HER2 Expressing Solid Tumors Business Wire
ADC Therapeutics Initiates Expanded Access Program for Loncastuximab Tesirine in the U.S. Business Wire
ADC Therapeutics SA (NYSE:ADCT) Receives Consensus Recommendation of "Buy" from Analysts MarketBeat
Bergenbio dream lives on, despite Genmab's broken Axl Vantage
Breast Cancer Treatment Advancements Emerge After New Study Finds Global Deaths Increased in 2019 PRNewswire
ADC Therapeutics Completes Enrollment in Pivotal Phase 2 Clinical Trial of Camidanlumab Tesirine (Cami) in Relapsed or Refractory Hodgkin Lymphoma Business Wire
Fitch Affirms Liquid Telecom at 'B+'; Outlook Stable Fitch Ratings
ADC Therapeutics Announces FDA Accepts Biologics License Application and Grants Priority Review for Loncastuximab Tesirine for Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma Business Wire
Synaffix and Mersana add license options for six ADC targets to existing deal The Pharma Letter
A Pfizer partner welcomes ex-ADC Therapeutics CMO Jay Feingold to the team; Amid tough sledding, Immunovant chooses Eli Lilly alum as CFO Endpoints News
ADC Therapeutics Announces Pricing of Upsized Initial Public Offering GlobeNewswire
Camidanlumab Tesirine Under Investigation in Relapsed/Refractory Hodgkin Lymphoma OncLive
ADC Competition Heats Up In China But Caution, Pressure Also Mount Scrip
Africa Data Centres Opens 10MW Colocation Facility in Lagos Data Center Knowledge
ADC Therapeutics Announces Proposed Public Offering Business Wire
ADC Therapeutics Announces Positive Results from Pivotal Phase 2 Clinical Trial of Single Agent Loncastuximab Tesirine GlobeNewswire
Manipur ADC Bill: ATSUM calls for 24-hr shutdown after talks fail - EastMojo
ADC Therapeutics Becomes Oversold (ADCT) Nasdaq
The European, Middle East and African Antitrust Review Global Competition Review
District Cooling Energy System Market to Witness Growth Acceleration | Emirates Central Cooling Systems Corporation (EMPOWER), Shinryo Corporation, Emirates District Cooling LLC (Emicool) ? Industrial IT Industrial IT
The proposed Manipur (hill areas) ADC bill, 2021 vis-ŕ-vis The Original Act Nagaland Post
ADC Therapeutics to Participate in the Jefferies London Healthcare Conference Yahoo Finance
ADC Therapeutics Announces Launch of Initial Public Offering GlobeNewswire
ADC Therapeutics Announces Updated Clinical Data on Lead Antibody Drug Conjugate Programs Loncastuximab Tesirine (Lonca) and Camidanlumab Tesirine (Cami) Presented at 62nd American Society of Hematology Annual Meeting Business Wire
Liquid's ADC to build 'biggest African data centre' outside South Africa Capacity Media
ADC to pump billions into 10 new Africa data centres TechCentral
AstraZeneca helps ADCT to $200M megaround to push anticancer ADCs to pivotal data FierceBiotech
Lonza extends antibody drug conjugate supply deal with biotech client Reuters
ADC Therapeutics Doses First Patients in Pivotal Phase 2 Clinical Trial of ADCT-301 in Patients with Relapsed or Refractory Hodgkin Lymphoma BioSpace
Adcendo Further Strengthens Management Team and Scientific Advisory Board with Appointment of International ADC Leaders PRNewswire
Synaffix to Present Key ADC Technology Data on SYNtecan ETM Linker-Payload at World ADC Conference PRNewswire
ADC Therapeutics Announces a $115 Million Convertible Credit Facility with Deerfield GlobeNewswire
ADC Therapeutics to Host Conference Call to Highlight Loncastuximab Tesirine (Lonca) Clinical Trial Data Being Presented at Virtual EHA Annual Congress Business Wire
ADC Therapeutics and Freenome Enter Biomarker Development GlobeNewswire
ADC Therapeutics Announces First Patient Dosed in Phase I Clinical Trial of ADCT-601 in Advanced Solid Tumors GlobeNewswire
ADC Therapeutics Cuts Price In Second IPO Attempt Seeking Alpha
Loncastuximab Tesirine Produces Durable Response in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Hematology Advisor
Genmab and ADC Therapeutics Announce Amended Agreement for GlobeNewswire
ADC Therapeutics Begins U.S. IPO Process Seeking Alpha
ADC's $233M IPO Brings It to NYSE With Cancer Drug Launch on Horizon Xconomy
ADC Therapeutics Announces Maturing Data from Pivotal Phase 2 Clinical Trial and Phase 1/2 Combination Clinical Trial of Loncastuximab Tesirine (Lonca) in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma Business Wire
TI's new precision wideband ADC pushes data-acquisition performance higher while cutting size and power consumption in half PRNewswire
IPO, check: Now, ADC Therapeutics files for lonca approval FierceBiotech
Byondis ESMO Late-Breaking Presentation Confirms ADC [Vic-] Trastuzumab Duocarmazine (SYD985) Superior to Physician's Choice in Pre-treated Locally Advanced or Metastatic HER2-Positive Breast Cancer PRNewswire
IPO Restart: ADC Therapeutics Refiles For U.S. IPO TheStreet
New Antibody-Drug Conjugate Offers Hope to Hard-to-Treat Cancer Patients Labiotech.eu
MilliporeSigma Announces New Innovation & Capacity to Advance Next Generation Antibody-drug Conjugate (ADC) Therapies Canada NewsWire
ProfoundBio Announces Completion of More Than $55 million Series A Financing to Advance Novel Antibody-Drug Conjugate (ADC) Portfolio PRNewswire
ADC Therapeutics cleared to resume US trial of camidanlumab tesirine The Pharma Letter
ADC Consortium to boost APAC IoT connections with new submarine cable FutureIoT
Innovent Announces License Agreement with Synaffix in an ADC Technology Deal PRNewswire
ADC Therapeutics and Adagene Announce License Agreement GlobeNewswire
ADC Therapeutics set to go public European Biotechnology
ADC Therapeutics and SOPHiA GENETICS Partner for Biomarker GlobeNewswire
Seeking Alpha Catalyst Watch Seeking Alpha
Innovate with C#; Microsoft ADC Set to Host Programmers and Developers in Africa PRNewswire
5 Dividend Stocks To Act As A Ballast For Your Portfolio Seeking Alpha
The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Benzinga
Antibody-Drug Conjugates (ADCs) Market Size to Reach USD 20.01 Billion in 2028 | Increasing Prevalence of Cancer Along with Growing Geriatric Population are Significant Factor Driving Industry Demand, says Emergen Research PRNewswire
Auto Scale your Applications with Citrix ADC on Google Cloud ITPro Today
ADC Therapeutics (NYSE:ADCT) shareholders are up 10% this past week, but still in the red over the last year Simply Wall St
Synaffix collaboration with ADC Therapeutics expanded The Pharma Letter
ADC Therapeutics taps Freenome to chart biomarkers for its lead lymphoma drug FierceBiotech
ADC Therapeutics Rakes in $303 Million with Addition to its Series E BioSpace
ADC Therapeutics Announces Final Close of Series E Financing Expansion BioSpace
DDB Worldwide Named 2021 Network of the Year by ADC PRNewswire
Adcendo raises EUR 51 Million in Series A Financing to Advance Novel Antibody-Drug Conjugates for Treatment of Cancers PRNewswire
Benzinga's Top Ratings Upgrades, Downgrades For August 9, 2021 - Benzinga Benzinga
FDA Approves Loncastuximab Tesirine for Relapsed/Refractory Large B-Cell Lymphoma OncLive
ADC Therapeutics SA (ADCT) Stock Price Today, Quote & News Seeking Alpha
3 Stocks At 52-Week Lows That Could Bounce Big - Benzinga Benzinga
Tyco Electronics to buy ADC Telecom for $1.25 billion MarketWatch
Himalaya Therapeutics Announces Submission in Mainland China of IND Applications for its CAB-AXL-ADC to treat sarcomas and NSCLC, its CAB-ROR2-ADC to treat melanoma and NSCLC PRNewswire
Identifying DLBCL Patients Most Likely to Benefit from ADCT-402 Goal of Partnership Lymphoma News Today
Cloud players reshape telecom's landscape ? Industry Voices: Walker FierceTelecom
ADC Therapeutics axes HER2 program BioPharma Dive
| For more news about ADC Telecommunica click here:
ADC Telecommunica News |
|
Website Width:
Background image: |
|  | |
|
|
